Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan;57(1):197-203.
doi: 10.1007/s11255-024-04152-z. Epub 2024 Jul 19.

Association of serum resolvin D1 with the risk of major adverse cardiovascular events in hemodialysis patients

Shan Jiang #  1 , Chunyu Luan #  2 , Tongtong Liu  1 , Tengfei Xu  1 , Jing Zhang  3 , Peng Zhang  4
Affiliations

Association of serum resolvin D1 with the risk of major adverse cardiovascular events in hemodialysis patients

Shan Jiang et al. Int Urol Nephrol. 2025 Jan.

Abstract

Purpose: Resolvin D1 (RvD1) inhibits inflammation, reduces oxidative stress, and forecasts the risk of cardiovascular events, but relevant evidence in hemodialysis patients is lacking. This study intended to investigate the predictive value of RvD1 for major adverse cardiovascular events (MACE) risk in hemodialysis patients.

Methods: Totally, 252 patients who underwent hemodialysis were included. Serum RvD1 was measured by enzyme-linked immunosorbent assay. Patients were followed up with a median of 12.1 months. MACE was recorded during the follow-up period.

Results: RvD1 was inversely correlated with diabetes history (P = 0.002), cardiac troponin T (TnT) (P = 0.029), and high sensitivity C-reactive protein (hsCRP) (P < 0.001) in hemodialysis patients. 25 hemodialysis patients experienced MACE. RvD1 was reduced in hemodialysis patients with MACE versus those without MACE (P = 0.004). RvD1 exhibited a certain value in forecasting MACE risk, with an area under curve (AUC) of 0.675 [95% confidence interval CI: 0.565-0.786]. Increased RvD1 cut by median (P = 0.043) and cut by quartile (P = 0.042) were related to decreased accumulating MACE in hemodialysis patients. Moreover, RvD1 independently predicted declined MACE risk [odds ratio (OR) = 0.644, P = 0.045], but age (OR = 1.048, P = 0.039) and TnT (OR = 1.006, P = 0.005) independently predicted ascended MACE risk in hemodialysis patients. The combination of these independent factors displayed a good value for estimating MACE risk in hemodialysis patients with an AUC of 0.744 (95% CI: 0.640-0.849).

Conclusion: Serum RvD1 is inversely correlated with diabetes history, TnT, and hsCRP in hemodialysis patients. More importantly, it could serve as a potential marker to predict MACE risk in these patients.

Keywords: Hemodialysis; Major adverse cardiovascular events; Marker; Resolvin D1; Risk prediction.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of interest: The authors declare that they have no conflict of interest. Ethical approval: The study was accepted by the Ethics Committee. 252 patients signed the informed consent form.

References

    1. Ammirati AL (2020) Chronic kidney disease. Rev Assoc Med Bras (1992) 66(1):s03–s09. https://doi.org/10.1590/1806-9282.66.S1.3 - DOI
    1. Ying M, Shao X, Qin H, Yin P, Lin Y, Wu J, Ren J, Zheng Y (2024) Disease burden and epidemiological trends of chronic kidney disease at the global, regional, national levels from 1990 to 2019. Nephron 148:113–123. https://doi.org/10.1159/000534071 - DOI - PubMed
    1. Himmelfarb J, Vanholder R, Mehrotra R, Tonelli M (2020) The current and future landscape of dialysis. Nat Rev Nephrol 16:573–585. https://doi.org/10.1038/s41581-020-0315-4 - DOI - PubMed - PMC
    1. Karageorgos FF, Neiros S, Karakasi KE, Vasileiadou S, Katsanos G, Antoniadis N, Tsoulfas G (2024) Artificial kidney: challenges and opportunities. World J Transpl 14:89025. https://doi.org/10.5500/wjt.v14.i1.89025 - DOI
    1. Chisavu L, Mihaescu A, Bob F, Motofelea A, Schiller O, Marc L, Dragota-Pascota R, Chisavu F, Schiller A (2023) Trends in mortality and comorbidities in hemodialysis patients between 2012 and 2017 in an East-European country: a retrospective study. Int Urol Nephrol 55:2579–2587. https://doi.org/10.1007/s11255-023-03549-6 - DOI - PubMed - PMC

LinkOut - more resources